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Stroke is an acute cerebrovascular disease caused by acute brain artery bursting or cerebral embolism that leads to
neuronal death and severe dysfunction of synaptic transmission. Neuronal damage after stroke remains a major
cause of morbidity and mortality worldwide and affects 795 000 of lives every year in United States. However,
effective treatments remain lacking, which makes the identification of new therapeutic targets a matter of great
importance.
N-methyl-D-aspartate glutamate (NMDA) receptor is important both in the normal synaptic transmission and in the
neuronal death after stroke. Accumulated evidences show NMDA receptor downstream effectors, such as PSD-95,
DAPK1, and ERK, had been revealed to be linked with neuronal damage. Based on our recent studies, we review
the promising targets of the NMDA receptor downstream signaling involved in stroke treatment. This review will
provide the concept of NR2B downstream signaling in neuronal death after stroke and provide evidences for
developing better NMDAR-based therapeutics by targeting downstream proteins.
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Stroke is one of the most life- threatening cerebrovascu-
lar disorders, the second leading cause of lethality and
major cause of disability in the world. In consequence of
interruption of cerebral blood flow, Stroke causes irre-
versible damage to the affected neurons. There are two
main types of stroke, ischemic and hemorrhagic. Ischemic
stroke accounts nearly for 85% of all reported stroke inci-
dents. This type of stroke occurs when a thrombus or
embolus blocks cerebral blood flow resulting in cerebral
ischemia and consequent neuronal damage and cell death.
Hemorrhagic stroke, accounts for the remaining 15%
stroke cases, occurs due to rupture of blood vessel in the
brain which produces rapid cerebral injury. Intraven-
ous recombinant tissue plasminogen activator (rtPA)
is the only FDA approved drug for treatment of is-
chemic stroke [1]. Patients who receive this drug
within the therapeutic window (<4.5 hours) also have
a high risk of intracranial bleeding, usually 6–8% against
0.6–2% spontaneous hemorrhages in stroke. Other* Correspondence: lym@hust.edu.cn
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unless otherwise stated.limitations associated with rtPA therapy like disruption of
blood brain barrier, seizures and progression of neuronal
damage are major concerns. Thus, there is a stringent
need for exploring novel neuroprotective strategies for the
treatment of ischemic stroke [2].
Recent studies on the blocking peptides of NR2B down-
stream cell death signaling pathway have revealed their
potential neuroprotective roles in ischemic stroke. The
cell death blocking peptides have shown promising effects
on protecting the neurons against excitotoxic insults, and
on decreasing infarct volume and improving neurological
functions in experimental models of ischemic stroke [3].
This review briefly focuses on the promising targets
involved in the downstream cell death signaling of NR2B
receptor subunit and their potential in the treatment of
cerebral ischemic stroke.
NR2B downstream signaling in stroke
The N-methyl-D-aspartate receptor (also known as the
NMDA receptor or NMDAR), a glutamate receptor, is the
predominant molecular switch for controlling synaptic
plasticity and memory function [4]. Excessive stimulation
of the NMDAR is an initial and crucial event for neuronal
death after cerebral ischemic stroke [5]. It is known that. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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ant role in calcium ions (Ca2+) permeation of cell physio-
logical reaction [6], while extrasynaptic NR2B subunit
receptor links signal transmission of cell death. In particu-
lar, the mechanisms that control the recruitment of cell
death or cell survival pathways upon activation of
NMDARs are thought to depend in part, on the Ca2+ con-
centration and its route of entry, but mostly on the sub-
unit composition and localization of the NMDARs that it
activates [7]. Several evidences have suggested that hetero-
meric NR1/NR2B receptors are initial triggers of cell
death pathways, while NR1/NR2A receptors mediates cell
survival signaling. First, in both mature cortical cultures
and in animals in vivo, the activation of NR2B-containing
NMDARs results in excitotoxicity, while the activation of
NR2A-containing NMDARs promotes neuroprotection
[8]. Second, NR2B-containing NMDARs are localized
preferentially at extrasynaptic sites while NR2A-
containing NMDARs are expressed at the synaptic area
[9], and activation of extrasynaptic NMDARs and associ-
ated downstream signaling cascades correlates with a pro-
death transcriptional response while activation of synaptic
NMDARs lead to pro-survival transcriptional response
[10]. Third, neurotoxicity induced by glutamate re-
lease from astrocytes involves extrasynaptic NR2B-
containing NMDARs [11]. Finally, glutamate sensitivity
in neurons increases in parallel with the expression level
of NR1/NR2B as NR2B-containing NMDARs have a
higher affinity for glutamate, slower deactivation kinetics,
and reduced Ca2+ -dependent desensitization when
compared to NR2A-containing receptors [12].
Hence blocking NR2B subunit is thought to be the best
target to block ischemic injury [13]. However, NR2B sub-
unit has been found to combine with NR1/NR2A subunit
and to form NR1/NR2A/NR2B receptor assembly at
synapses [14]. A large family of synthetic compounds that
selectively inhibit NMDARs containing the NR2B subunit
[15]. Among them, several highly potent molecules show
good efficacy as neuroprotectants in a variety of ani-
mal models. It is noteworthy that in humans, NR2B-
selective antagonists do not induce the adverse side effects
usually seen with nonselective NMDAR antagonists, even
at maximally neuroprotective doses [16]. Despite
these encouraging data, NR2B-selective antagonists
have not succeeded in clinical trials yet because of uncer-
tain biosafty and pharmacokinetic profiles [17]. Conse-
quently, the selectivity of NR2B subunit antagonist acting
on extrasynaptic NMDA receptor is facing challenges.
New potent NR2B-selective antagonists are still in great
demand [18].
Overactivation of NMDAR induces calcium overload,
oxidative/nitrosative stress and excitotoxicity in neuronal
cells. These are considered as the major pathogenesis of
cerebral ischemic stroke [19-21]. Excitotoxicity is one ofthe essential theories of cell death in stroke (including is-
chemic stroke and hemorrhagic stroke) [22]. It’s generally
recognized that glutamate, a kind of excitatory neuro-
transmitters, excessively accumulates in ischemic tissue
to activate postsynaptic glutamate receptors, including
α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid
receptor (AMPA receptor) and NMDA receptor at ische-
mic and anoxic state. Especially, NMDA receptor allows
a mass of Ca2+ influx, leading to Ca2+ overload [22] and
activating a series of signaling molecules. Calcium over-
load causes mitochondria damage, generation of reactive
oxygen species (ROS) and reactive nitrogen species (RNS),
and then leads to cell necrosis and autophagy [23,24].
These ROS and RNS have two effects, one is inhibiting
the signal transduction of cells regulating in oxidation; the
other is directly inducing necrosis [25]. In stroke injury, it
is known that main sources of ROS include the mitochon-
dria electron transport chain and the oxidative phosphor-
ylation of NADPH-oxidase. Hence, NADPH-oxidase is
thought to be a potential target for stroke treatment. Ac-
cumulated facts prove that oxidative stress is the major in-
ducement of stroke damage. Since oxidative stress
participates in chronic inflammation and metabolic disor-
ders [26]. Astrocytes, neuronal support cells, contribute to
inflammation during stroke insult. Astrocytes, under nor-
mal conditions, perform physiological functions like, glu-
tamate uptake, glutamate release and maintain cellular
and ion homeostasis [27]. During cerebral injury, astro-
cytes undergo morphological changes and become acti-
vated. Activated astrocytes release proinflammtory
cytokines and chemokines thus results in initiation and
progression of inflammation [28]. In cerebral ischemia,
microglia, residential brain macrophages, become activated
and release detrimental neurotoxic mediators like proin-
flammtory cytokines, superoxide, nitric oxide (NO), TNF-
α and proteases [29]. Many of these mediators can in turn
influence the microglia morphology and activate it in a
paracrine and autocrine fashion. The inhibition of this
pathway of neuronal damage can be considered as a logical
option. NO is a small molecule, secreted by microglia cells,
acts directly on neurons as neurotoxin or indirectly by po-
tentiating excitotoxic transmitters. Inhibition of microglia
activation in ischaemia may provide a novel target in man-
agement of stroke [30].
Researchers have been working on clearing ROS to
block this vicious circle and hope for fighting stroke for
years. However, lots of clinical trials show that clearing
ROS does not help for preventing the progress of stroke
damage, but even worsens it in some situation [31]. Be-
cause ROS has important physiological function in main-
taining tissue homeostasis, clearing ROS will damage the
normal functions of the central nervous system, such as
balancing the electrolyte balance, stabling the osmotic
pressure and so on [32]. Therefore, we hold the opinion
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dative stress through selectively enhance the capability of
endogenous antioxidant system without impairing the
normal functions of ROS in the brain. In addition, mito-
chondrial abnormality can induce DNA damage through
activating apoptotic signaling pathway, and then induce
cell apoptosis at late stage.
Although activation of glutamate receptor is the major
cause of cell death (including necrosis, apoptosis and au-
tophagy) in stroke (Figure 1), almost all clinical strat-
egies which attempt to block NMDA receptors are failed
in stroke treatment [33]. The main reason is that block-
ing NMDA receptors also interrupts physiological func-
tion of synaptic transmission. Therefore, we supposed
that explore the specific downstream substrates of
NMDA receptor and selectively block cell death signal-
ing pathway without affecting physiological functions
might be the ideal way on stroke therapy.
Downstream signals of NR2B receptor subunit in stroke
NR2B subunit is a modular structure consisting of four
distinct domains: an extracellular N-terminal domain, an
extracellular ligand binding domain, a transmembrane
domain and an intracellular C-terminal domain of variable
length [34,35]. The transmembrane domain, containing
three membrane-spanning helices and a membrane re-
entrant loop, contributes to the channel pore formation.
The cytoplasmic domain is required for protein-protein in-
teractions. This interaction with the intracellular domain of
NMDAR subunits is subject to extensive posttranslationalFigure 1 Excitatory neurotransmitter (glutamate) acts at extrasynapse
NMDA receptor leads to excessive Ca2+ loading into cells. Overloading of C
of ROS/RNS. On the other hand, excessive intracellular Ca2+ also activate Ca
apoptosis. DNA damage also promotes the expression of apoptosis and automodifications such as phosphorylation, which is essential to
regulate downstream signaling [36]. The carboxyl terminus
of NMDA subunit binds important intracellular signaling
complexes, allowing for their efficient and selective activa-
tion by calcium influx through the opening of NMDAR
channels [37]. Therefore, selective inhibition of NMDAR
mediated neuronal injuries may be achieved.
NR2B-DAPK1 signaling
Recently, a new signaling molecule engaged in the
neuronal death cascade was identified by using coim-
munoprecipitation with NR2B-specific antibodies and
mass spectrometry. It is found that after stroke injury,
NMDAR interacts with Death Associated Protein Kinase
1 (DAPK1) through NR2B subunit, a member of a serine/
threonine kinase family well known for their roles in cell
death [38]. Stroke injury activates DAPK1, which migrates
to extrasynaptic site and binds to NR2B receptor subunit.
Through GST-pull down experiments combined with co-
immunoprecipitation, our colleagures demonstrate that
DAPK1 directly interacts with the NR2B via an interaction
in the amino acids fragment from 1297 to 1304 in C-
terminal of NR2B subunit (NR2Bi) specifically. By defining
the exact binding domain of DAPK1 in NR2B, an interfer-
ence peptide (NR2BCT) was designed to effectively disrupt
the interaction of DAPK1 with NMDARs during stroke. It
is worth noting that NR2BCT could alleviate infarction
area and improve neurological score after ischemic stroke.
In short, the combination of DAPK1-NR2B receptor
subunit mediates pathological process of stroke injury,s and over-activates NMDA receptors in stroke. Over-activation of
a2+ induce mitochondria injury, thus causes necrosis and generation
2+ channels on nuclear membrane, causing DNA damage and cell
phagy related genes, and finally induce cell apoptosis and autophagy.
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cells (Figure 2), and most importantly, it is not relevant to
physiological function of NMDA receptor because the
interrupting of DAPK1 with NR2B does not alter the syn-
aptic transmission of NMDA receptor [39]. Our recent
work further demonstrated that the signaling events
downstream of DAPK1 involve the interaction of DAPK1
with p53 (a tumor suppressor) and the followed activation
of proapototic transcription-dependent and -independent
pathways. Through disruption of the DAPK1–p53 inter-
action by a small membrane-permeable peptide inhibitor
(Tat-p53DM) effectively blocked these two distinct path-
ways of neuronal death in ischemia [40]. Thus, DAPK1
can be considered as a signaling amplifier of downstream
signaling of NR2B subunits at extrasynaptic sites for me-
diating brain damage in stroke, and targeting NR2B-
DAPK1-p53 signaling can be considered as a practical
strategy for stroke therapy.
NR2B-PSD95-nNOS signaling
Interaction of NMDA receptor NR2B subunit and post-
synaptic density protein-95 (PSD-95) has been firstly
demonstrated on focal cerebral ischemic injury by using
the yeast two-hybrid screen technique [41]. Furthermore,
PSD-95 acts as a scaffolding protein links the NR2B carb-
oxyl terminus to the death-signaling protein nNOS. nNOS
is an enzyme that catalyzes the production of highly
neurotoxic molecule nitric oxide (NO) [42].
Studies have shown that disruption of the NR2B-PSD-
95-nNOS signaling complex inhibits NMDAR-mediated
NO release and prevents neuronal death. For example,
Tat-NR2B9c, that competes with native NR2B subunits
for binding to PSD-95 and dissociates PSD-95-nNOS
from NR2B, could systemically reduce ischemic brain
damage in rat model of stroke [43]. In addition, ZhouFigure 2 Blockade of NMDA receptor or NMDA-DAPK1 downstream s
Blockade of NMDA receptor in stroke causes 1) inhibition of necrosis, apop
surviving and regeneration signaling; 3) interruption of physiological functi
downstream signaling in stroke specifically mediates 1) prevention of cell d
inhibition of cell survival; and 3) no adverse effects on physiological functioand his colleagues further examined the essential role of
this NMDAR signaling complex in ischemic neuronal
damage. By co- immunoprecipitation, the authors found
that the interaction between PSD-95 and nNOS is greatly
enhanced in the brain after stroke. Interestingly, the
increase in PSD-95–nNOS interaction in neurons after
stroke requires both activation of NR2Bsubunit containing
NMDARs (NR2BRs) and active association of NR2B with
PSD-95 [44]. Interestingly, by competing with nNOS for
binding to PSD-95, the nNOS-N1–133 peptide effectively
limited the interaction between PSD-95-nNOS and re-
duced the brain damage after stroke [45,46]. These results
add to the growing evidence that NR2B–PSD-95–nNOS
interaction is required for ischemic brain damage medi-
ated by the NMDAR [47]. Nevertheless, as NMDA stimu-
lation can induce nNOS activation at doses lower than
that required to induce neurotoxicity, and such NMDAR-
mediated nitric oxide production may be involved in brain
functions such as synaptic plasticity required for learning
and memory [48,49]. Thus, future studies are needed to
solve these questions.
NR2B-ERK signaling
ERK1/2 signaling pathway, is activated by Ca2+ influx
through NMDARs, plays an important role in NMDAR-
dependent neuronal survival. Extrasynaptic NMDAR ac-
tivity inactivates ERK signaling pathway, while activation
of synaptic NMDARs induces sustained ERK activation
[50,51]. Consistent with being more abundant at extrasy-
naptic sites, NR2B has been shown to be selectively as-
sociated with synaptic Ras GTPase activating protein
(SynGAP) [52], which represses ERK signaling. In ad-
dition, suppression of NMDA-dependent ERK activation
by the dominant-negative form of RasGRF1 suggests that
RasGRF1 is a crucial intermediate between the NMDARignaling induces different fates of neuronal cells in stroke. (A)
tosis and autophagy of neuronal cells; 2) suppression of endogenous
ons of synaptic transmission. (B) Blockade of NMDA(NR2B)-DAPK1
eath (such as necrosis, apoptosis and autophagy); 2) probable
ns of synaptic transmission.
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exchange factor (GEF) and Ras activator. RasGRF1 is se-
lectively expressed in the central nervous system (CNS)
and is enriched in synapses. RasGRF1 activates Ras only
when it binds Ca2+/calmodulin and is thus a potential
target of Ca2+ entering neurons [53]. The interaction
between NR2B and RasGRF1, and the demonstration
that disruption of this interaction attenuated NMDA-
dependent ERK activation, strongly suggests that the
NR2B subunit directly links the NMDAR to ERK acti-
vation [54].
As is known, stimulation of either synaptic or extrasy-
naptic NMDARs is linked to the activation of ERK/mito-
gen-activated protein kinases (MAPK), which therefore
appear to play a dual role as prosurvival [55] and pro-
death kinases [56]. Another interesting finding is that
tau toxicity is accompanied by sustained and delayed ac-
tivation of ERKs and that this activation is NMDAR
dependent and critically involved in cell death. Tau pro-
tein supports the microtubule system responsible for
intracellular transport, axonal morphology, and cell
physiology. The correct functioning of tau depends
upon a balance between the different tau isoforms, its
state of phosphorylation, and its structural integrity. A
perturbation of these parameters may cause tau dys-
function and tau toxicity [57]. More importantly, tau in-
fluences NMDAR signaling and induces a necrotic type
cell death [13] is demonstrated by (i) the rapidity of
neurotoxic effect, (ii) the lack of classical hallmarks of
apoptosis, (iii) the neuroprotective role offered by an
inhibitor of extrasynaptic NR2B receptor, and (iv) the
dephosphorylation of CREB. Furthermore, two MEK in-
hibitors, U0126 and PD98059, as well as genetic abla-
tion of ERK1, inhibit tau toxicity, in agreement with
previous report that ERKs exert critical role in oxidative
glutamate toxicity in cortical neurons and in other para-
digms of neuronal death [58,59].
So far, there is no direct evidences show the roles of
NR2B-ERK signaling in ischemic stroke models. How-
ever, the above research results may throw light on this
potential signaling pathway mediating neuronal cell
death, and provide clues that interrupt NR2B-ERK path-
way may be another target for preventing neuronal death
after stroke. Therefore, next studies should focus on this
area to address this issue.
Conclusion
In conclusion, directing at NMDA receptor, many stroke
protecting drugs (219 drugs were tested in clinical trials
around the world) have been developed and used to fight
against stroke. However, none of these drugs have
achieved success. Because all these drugs severely inter-
rupt the physiological functions of NMDA receptor and
leading to serious side effects such as cognitive disorder,hallucination, dyspnea and even coma [20]. In this re-
view, we summarized several experimental stroke studies
and identified specific components of NMDARs down-
stream signaling complexes responsible for neuronal
death. These reports have led to the recent development
of several therapeutic peptides that exert neuroprotec-
tive actions by specifically disrupting the downstream
neuronal death signaling pathways of NMDARs without
affecting the physiological functions.
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